Health Care

The Nasdaq Hearings Panel granted SCWorx Corp.'s request for reconsideration and approved the company's continued listing on The Nasdaq Capital Market, reversing the Panel's September 17, 2026 delisting decision. The Panel determined that SCWorx now meets Nasdaq's continued listing requirements, including the minimum bid price rule 5550(a)(2) and the minimum publicly held shares rule 5550(a)(4). Trading in SCWorx common stock on Nasdaq, suspended since April 14, 2026, will be reinstated on a date to be scheduled by Nasdaq, and the stock will continue to be quoted on the OTCQB Venture Market under the symbol WORX until then. The decision followed the company's September 16, 2026 private placement, which together with warrant exercises raised publicly held shares to 549,092 as of September 17, 2026, above the 500,000-share minimum, and the closing bid price has been at or above $1.00 per share every trading day since August 4, 2026. As conditions, the Panel required disclosure that each private placement investor agreed not to exercise its termination right, imposed a Discretionary Panel Monitor for a one-year period ending October 2, 2027, and required monthly reports of shares outstanding, insider holdings and public float through October 5, 2027.

AstraZeneca has opened its newest global strategic research and development center in Kendall Square, Cambridge, Massachusetts, part of a more than $1 billion investment in the state that will expand its Massachusetts workforce by over 50 percent in the coming years. The 570,000 square foot, 18 story site at 290 Binney Street will house nearly 2,000 researchers and scientists alongside the company's genomic medicine site at 100 Binney Street, and includes ten floors of interconnecting laboratories integrating robotics, continuous automation and agentic AI. The scientists will work on AstraZeneca's oncology, cell therapy, chronic disease and rare disease pipeline, targeting conditions such as COPD, obesity and metabolic disease, breast cancer and rare diseases, while pursuing future innovation in cell therapy and biologics to fuel growth beyond 2030. The Massachusetts investment sits within AstraZeneca's broader $50 billion US investment, and the new site joins its other US-based global strategic research center in Gaithersburg, Maryland, as part of a coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. Chief Executive Officer Pascal Soriot said Kendall Square is a leading innovation ecosystem and one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs, while Massachusetts Governor Maura Healey called the investment a major vote of confidence in the state.

Novartis entered a licensing and option agreement with China-based Abogen Biosciences, giving the Swiss pharma giant exclusive worldwide rights to Abogen's lead candidate ABO2203 and options to license additional programs built on Abogen's proprietary RNA platform. Under the agreement, Abogen will receive an upfront payment of $575 million and is eligible to receive up to approximately $7.2 billion in potential milestone payments if all options covering additional programs are exercised and the specified development, regulatory and commercial milestones are achieved, plus royalties on future product sales. ABO2203 is an investigational messenger RNA-encoded CD19xCD3 T-cell engager being developed for autoimmune diseases, designed to reset B cells by directing endogenous production of T-cell engagers in vivo. The transaction remains subject to customary closing conditions, including required regulatory clearances. The deal comes as Novartis faces generic competition for Entresto and Promacta and back-to-back pipeline setbacks, including the late-stage failure of pelacarsen and the HARBOR study of del-desiran in myotonic dystrophy type 1.

Veeva Systems announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries, expanding the French pharmaceutical group's relationship with Veeva beyond its existing use of Veeva Link Key People. The deployment is expected to improve data consistency, connect customer information with actionable insights and support more targeted commercial and medical engagement. Veeva OpenData is one product within Veeva's broader Data Cloud portfolio, which also includes Veeva Link and Veeva Compass, each addressing different aspects of life sciences data requirements. The win could deepen Veeva's footprint within large pharmaceutical organizations and support recurring revenue growth in its Data Cloud business as drugmakers scale artificial intelligence and advanced analytics. Veeva currently has a market capitalization of $44.25 billion, and its shares have gained 22.4% year to date.

Inspire Medical Systems announced that the American Medical Association's CPT Editorial Panel approved new Category I CPT codes for procedures involving a single lead and implantable pulse generator, including the company's recent launch of the Inspire V system. The new codes, effective Jan. 1, 2028, establish a dedicated coding framework for hypoglossal nerve stimulation procedures and are expected to create a clearer, more consistent pathway for coding and reimbursement while reducing administrative burden for hospitals and physicians. The company credited support from the American Academy of Otolaryngology-Head and Neck Surgery, the American Academy of Sleep Medicine and the International Surgical Sleep Society in seeking a permanent coding solution. The codes now enter the Medicare valuation process, with the Centers for Medicare & Medicaid Services expected to weigh recommendations from the AMA Relative Value Scale Update Committee; Inspire Medical expects CMS to publish proposed valuations in July 2027 and final valuations in November 2027. Inspire V, a closed-loop implantable device designed to synchronize with patients' natural breathing to help maintain an open airway during sleep, has treated more than 140,000 patients over more than a decade of clinical experience. INSP stock has lost 1.1% since the announcement on Thursday and is down 24.2% year to date, against the industry's 18.4% growth and the S&P 500's 12.3% rise, with a market capitalization of $2.02 billion.

Tempus AI has received 510(k) clearance from the Food and Drug Administration for two next-generation AI cardiovascular products, Tempus ECG-MR and Tempus ECG-PH. Tempus ECG-MR analyzes standard 12-lead resting electrocardiograms to detect signs associated with undiagnosed moderate or severe mitral regurgitation, while Tempus ECG-PH is an AI-enabled software device that analyzes standard 12-lead ECG data and provides a binary output for signs associated with pulmonary hypertension. The clearances come as the AI-ECG analysis market is expected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a compound annual growth rate of 19.3%, according to the Business Research report. Among peers, GE HealthCare's Advanced Imaging Solutions segment, which combines the former Imaging and AVS businesses, generated $3.77 billion in revenues in the second quarter of 2026, up 5.0% organically, with segment EBIT margin rising 90 basis points to 13.9%. iRhythm Holdings, whose platform is supported by more than 3 billion hours of curated ECG data and more than 12 million patient reports, expanded work with Desert Oasis Healthcare and signed two commercial agreements through Luum during the second quarter of 2026. Tempus shares have declined 17.7% over the past year, and the stock currently trades at a forward 12-month price-to-sales ratio of 7.30X versus an industry average of 4.82X.

Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.

CellCarta has established a strategic partnership with Waters Corporation to jointly pursue companion diagnostic and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs, aiming to give sponsors a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. Waters will provide underlying technology capabilities including instrumentation, reagents, standardized panels, assay development, software analysis, and where appropriate custom reagent and IVD commercialization, while CellCarta will integrate and deploy assays across its global CDx Lab Network, supporting Phase I-III clinical trial testing, analytical and clinical evidence generation, regulatory and logistics support, and commercial laboratory services. The companies cited existing platform alignment between CellCarta's CAP-accredited laboratory in Jining, China and BD flow cytometry platforms as a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs. Todd Chermak, President of CellCarta, said the partnership offers sponsors a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization, and that the companies are already engaging pharmaceutical and biotechnology companies on near-term opportunities.

Abbott announced U.S. Food and Drug Administration approval for updates to its CardioMEMS HF System that, for the first time, let U.S. CardioMEMS patients view their pulmonary artery pressure readings directly on their smartphones through the new CardioGuide HF App. The new capabilities also include Dynamic Treatment Plan, a software feature that lets clinicians set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure and send medication adjustment instructions directly to patients through the app. The CardioMEMS HF System, which measures pulmonary artery pressure through an implanted sensor in the pulmonary artery, has been shown to reduce heart failure hospitalizations and mortality risk, and clinicians have used its readings for more than a decade to identify signs of worsening heart failure and guide treatment. Abbott said it plans to make the CardioGuide HF App and Dynamic Treatment Plan available later this year. Katie Spayde, vice president of Abbott's heart failure division, said the new capabilities help patients stay informed, engaged and connected to their care between doctor visits.

Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.

Eli Lilly announced that the FDA has expanded the label of its oral cancer drug Jaypirca, also known as pirtobrutinib, to include a new indication in chronic lymphocytic leukemia or small lymphocytic lymphoma. Jaypirca has been approved to treat adults with previously untreated CLL/SLL who do not have a known 17p deletion, allowing the drug to be used as a first-line treatment for eligible patients. The approval is supported by data from the phase III BRUIN CLL-313 study, which showed that Jaypirca reduced the risk of disease progression or death by 80% compared to chemoimmunotherapy. Before this latest approval, Jaypirca was already approved for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor, and for adults with relapsed or refractory mantle cell lymphoma following two lines of systemic therapy including a BTK inhibitor. Jaypirca is already generating meaningful sales for Lilly, with revenues rising 66% year over year to $357 million in the first half of 2026, though its sales remain relatively small compared with Lilly's much larger obesity and diabetes portfolio.

Pacira BioSciences signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K. Under the deal, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales in the licensed territories. Pacira will continue to manufacture EXPAREL, while Molteni will oversee regulatory, market access, and commercialization activities. Molteni plans to launch EXPAREL sequentially in Italy, Germany, Austria, and Poland, with plans to seek approval in Switzerland. The first commercial sale is expected in 2027.

Shionogi & Co., Ltd. announced that its Board of Directors approved an agreement to acquire IntraBio Inc., a biopharmaceutical company developing and commercializing therapies for neurodegenerative diseases, for an upfront consideration of USD 2.0 billion payable to IntraBio shareholders. Under the agreement signed on October 5, 2026, IntraBio would become a wholly owned subsidiary of New Jersey-based Shionogi Inc., with the transaction scheduled to close between November 2026 and December 2026, subject to competition-law waiting periods and other customary conditions. The deal would add AQNEURSA (levacetylleucine) to Shionogi's rare disease portfolio; the drug was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease type C and by the European Medicines Agency in January 2026, and on September 18, 2026 it became the first and only FDA-approved treatment for Ataxia in patients with Ataxia-Telangiectasia, for which it is also under EMA review. Shionogi said the acquisition builds on the rare disease foundation it established through its April 2026 acquisition of global rights to edaravone, known as RADICAVA in the U.S. and RADICUT in Japan, and would strengthen its pipeline across Pompe disease, Fragile X syndrome, Jordan's syndrome and early-stage rare neurodegenerative programs. The impact on Shionogi's consolidated financial results for the fiscal year ending March 2027 is currently under review.

Dental Corporation Public Company Limited, or D, has met the criteria of the Stock Exchange of Thailand and will move from the Market for Alternative Investment, or mai, to trade on the SET in the Services industry group, Medical business sector, starting October 1, 2026, after more than 9 years listed on mai. Chief Executive Officer Pornsak Tantapakul, together with the company's board and executives, joined in congratulating the occasion. The company stated that the move to the SET reflects the organization's growth and potential, from its beginnings as a Thai family business to a listed company in the capital market, and that over the past 9 years it has used funds raised to expand its business, generating growth in revenue, net profit, and shareholders' equity. The Dental Corporation group operates a full-service dental business, covering dental hospitals, the Bangkok International Dental Hospital, or BIDH, dental centers, Smile Signature dental clinics, and Dental Planet dental clinics, as well as Dental Vision Company Limited, a subsidiary that distributes dental materials and equipment.

T. Man Pharmaceutical Public Company Limited, or TMAN, has announced the creation of a New S-Curve, moving into the longevity and wellness hub megatrend, with a target of driving revenue growth to 4 billion baht within the next 3-5 years, up from 2.5 billion baht in 2025. Prapol Thanachotiphan, Chief Executive Officer of TMAN, told InfoQuest that in the first 1-3 years the company will continue to grow from its core business by expanding hospital channels to raise their revenue share to 15-20% from 10% previously, while pushing the Propolis brand to become a full regional and international brand, from its current exports to more than 7 countries, and more than 10 countries across all products. Meanwhile, its OEM contract manufacturing business has grown by more than 100%, and it recently secured a major customer, Berham, in the distribution business for other brands. For the creation of the New S-Curve, the company will launch a new supplement brand at the end of this year, focusing on dietary supplements, vitamins and biotechnology under its own brand, targeting growth of 5-10% per year for this group over the next 5 years, and has assigned its subsidiary Nova Health to accelerate collaboration with leading research institutes to develop health innovations that address longevity, together with external partners.

Summit Therapeutics announced the closing of AstraZeneca's $2.0 billion strategic equity investment in the company. Under the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the day the investment was announced. The proceeds will support accelerated development of ivonescimab, a potential first-in-class investigational PD-1 / VEGF bispecific antibody, across solid tumor settings including combinations with antibody drug conjugates such as sonesitatug vedotin and Datroway. Summit Chairman and Co-Chief Executive Officer Robert W. Duggan said the investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment. Baker Hostetler LLP is serving as legal advisor to Summit.

Shionogi announced on the 5th that it will acquire US biopharmaceutical venture IntraBio. It will acquire all shares for 2 billion dollars, or about 316 billion yen, making it a wholly owned subsidiary. IntraBio was founded in 2015 and has strengths in the research and development of rare neurological disease drugs, with sales of 67.86 million dollars for the fiscal year ending December 2025. Shionogi is working to strengthen its rare disease drug business as a priority area outside of infectious diseases, and since April of this year it has begun global sales of a treatment for amyotrophic lateral sclerosis (ALS).

Safe Fertility Group Public Company Limited, or SAFE, has announced a three-to-five-year plan to expand its family care base from 40,000 families to 50,000 families, while driving average revenue growth of 10-15% per year from 2027 onward, after revenue in 2026 is expected to hold steady from the 900 million baht recorded in 2025. Dr. Wiwat Kwangkananurak, Chief Executive Officer, said the growth strategy comes from the Preserve and Prevent markets, as younger generations increasingly turn to egg freezing, sperm freezing, and genetic testing, as well as from expanding the base of international patients, who currently account for 50% of all patients. The company is also broadening its business scope into genetic analysis laboratories under Next Generation Genomic Company Limited, providing reproductive medicine and maternal and child medicine analysis services to leading public and private healthcare providers, as well as obstetrics and gynecology clinics both domestically and overseas. It is also in discussions on cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, with services under the NHSO project expected to begin in 2027. It is also discussing ways to provide intrauterine insemination, or IUI, for holders of universal health coverage rights, or the 30-baht scheme, to broaden access to treatment more comprehensively.

Safe Fertility Group Public Company Limited, or SAFE, has announced a business plan under the concept The Next Chapter of Fertility, riding the trend of younger generations marrying and having children later in life. The company aims to grow its customer base from roughly 40,000 families today to 50,000 families within 3-5 years, and targets average revenue growth of 10-15% per year through two main strategies: expanding the Preserve and Prevent market, which covers egg freezing, sperm freezing and genetic testing, and expanding its international customer base into new markets. International customers currently account for about 50% of the company's total patient base. In Thailand's assisted reproductive technology, or IVF, market, Kasikorn Research Center estimates the value at approximately 6 billion baht, while the global IVF market is worth more than 30 billion US dollars. SAFE cited Japan as an example, where the number of newborns has fallen below 700,000, yet children born through assisted reproductive technology now make up about one in eight of all births. The company has also expanded into genetic analysis laboratories through Next Generation Genomic Company Limited, and has set a long-term goal of 5-10 years to elevate Thailand into a Regional Fertility Hub.

Dental Corporation Public Company Limited, or D, has moved from the Market for Alternative Investment, or mai, to trade on the Stock Exchange of Thailand, or SET, in the Services industry group, Medical sector, effective October 1, 2026, after being listed on mai for more than 9 years. Chief Executive Officer Pornsak Tantapakul, along with the company's board and executives, joined in congratulating the company on meeting the SET's listing criteria. The move to the SET reflects the organization's growth and potential, from its beginnings as a Thai family business to a listed company in the capital market. Over the past 9 years, the company has used funds raised to expand its business, driving growth in revenue, net profit, and shareholders' equity. D operates a comprehensive dental services business covering dental hospitals, the Bangkok International Dental Hospital, or BIDH, dental centers, Smile Signature dental clinics, and Dental Planet dental clinics, as well as Dental Vision Company Limited, a subsidiary that distributes dental materials and equipment.

AnnJi Pharmaceutical announced it is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201, also known as rosolutamide, in patients with spinal and bulbar muscular atrophy, or SBMA, also called Kennedy's disease. The company said it submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now activate U.S. sites for the global trial. The ROMA-KD study is a global, multicenter, randomized, double-blind, placebo-controlled trial expected to enroll approximately 200 ambulatory patients with symptomatic SBMA worldwide, with the United States as a key region, and is intended to support potential global regulatory submissions. AJ201, an investigational oral small molecule and a potential first-in-class treatment for SBMA, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the United States and the European Union. AnnJi said the Phase 3 program builds on encouraging results from its completed Phase 2 study announced in May 2025, and the company also noted its SBMA Patient and Care Partner Advisory Council, first announced in collaboration with the Kennedy's Disease Association at the 2026 KDA International Patient and Scientific Conference.

AnnJi Pharmaceutical is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201, also known as rosolutamide, in patients with spinal and bulbar muscular atrophy, or SBMA, also called Kennedy's disease. The company said it submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now activate U.S. sites for the global trial. ROMA-KD is a global, multicenter, randomized, double-blind, placebo-controlled study expected to enroll approximately 200 ambulatory patients with symptomatic SBMA worldwide, with the United States as a key region, and is intended to support potential global regulatory submissions. AJ201, an investigational oral small molecule and a potential first-in-class treatment for SBMA, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the United States and the European Union. The Phase 3 program builds on encouraging results from the completed Phase 2 study announced in May 2025, and AnnJi said it has also established an SBMA Patient and Care Partner Advisory Council in collaboration with the Kennedy's Disease Association.

Cardinal Health announced in October 2026 that it had entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, maintaining the current scope of distribution services. The long-dated extension reinforces the durability of Cardinal Health's core distribution relationships and underscores the importance of scale partnerships in its business model. The company's narrative projects $297.6 billion in revenue and $3.0 billion in earnings by 2029, requiring 5.4% yearly revenue growth and an earnings increase of about $1.3 billion from $1.7 billion today. The extended CVS agreement supports that core distribution pillar but does not directly change the near-term focus on product quality risks from the levothyroxine and Webcol recalls, or cost pressure in the Global Medical Products and Distribution segment. The most relevant recent announcement alongside the CVS extension is Cardinal Health's August 2026 unsecured US$4.0 billion revolving credit agreement through 2031, which refreshes its funding flexibility and gives the company financial room to keep investing in automation, specialty distribution and at-home solutions.

Moderna Inc. ranked as the second top-performing stock in the US market in the third quarter, with shares surging 174.98 percent over the three months ending September. The rally was driven by news that its Intismeran Autogene combined with Merck's Keytruda achieved the primary endpoint of recurrence-free survival and the secondary target of distant metastasis-free survival in a late-stage clinical trial, marking the first positive readout from a phase 3 trial combining an mRNA-based cancer treatment with individualized neoantigen therapy and the first late-stage phase to show a clinically meaningful improvement over Keytruda alone. Melanoma, the target indication, is expected to increase by 112,000 cases by the end of the year, including an estimated 8,500 deaths, after some 330,000 cases were diagnosed globally in 2022. In August, Moderna received FDA approval of its biologics license application for the 2026 to 2027 formulas of its Spikevax and mNEXSPIKE COVID-19 vaccines. The vaccine maker is set to join the Nasdaq 100 index on Friday, October 9, replacing Warner Bros. Discovery Inc., which is set to merge with Paramount Skydance Corp. on Tuesday, October 6.

Asia Plus Securities said the number of Middle Eastern tourists in September rose 18.8% year on year, though it fell 43.1% from the previous month on seasonal factors. That brought the third quarter of 2026 up 12.9% year on year and 142.4% quarter on quarter, reflecting a gradual return of travel to normal and a positive signal for the Middle Eastern patient trend at private hospital groups. The research team views this as a positive factor for third-quarter 2026 earnings after Middle Eastern patients began to recover from the impact of the Iran war, with most returning patients being complex and critical cases that carry high revenue per case and high margins, supporting the prospect that profits will recover faster than revenue. This is consistent with the number of Middle Eastern tourists in the third quarter of 2026, with the UAE up 29.8% year on year and Saudi Arabia up 21% year on year, while Qatar and Oman rose 1% and 4% year on year respectively. The research team maintained an overweight stance on the hospital group and buy ratings on BH, PR9 and BDMS, choosing BH as the top pick because it has the highest share of revenue from Middle Eastern patients in the group at about 23%, followed by PR9 at about 10% and BDMS at about 4%. It kept 2027 target prices at 225.00 baht, 23.00 baht and 25.00 baht respectively.

Arcus Biosciences announced it will host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. The data package spans TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a pharmacodynamic correlations with overall survival. Arcus also plans to complete enrollment in the PEAK-1 Phase 3 trial and start PEAK-20 by year end 2026, with the ARC-20 datasets feeding into how credible those registrational bets look. The company's narrative projects $290.3 million revenue and $50.1 million earnings by 2029, yielding a $39.91 fair value and a 63% upside to its current price, while some of the lowest ranked analysts assume revenue could fall to about US$120.2 million by 2028.

AtriCure's fair value price target has shifted from about US$51.67 to about US$54.89, reflecting modest fine tuning in analyst models rather than a wholesale reset. BTIG raised its AtriCure price target to US$55 from US$45, pointing to the new STS Quality Metric, which it thinks could support greater use of the EnCompass Clamp in U.S. surgery patients with preoperative atrial fibrillation, and noting that only about 35% of atrial fibrillation patients undergoing cardiac surgery in the U.S. currently receive a surgical ablation. BTIG models potential upside to AtriCure's U.S. Open Ablation revenue of US$10m to US$25m in 2027 and US$20m to US$55m in 2028 compared with its prior forecasts. UBS keeps a Buy rating on AtriCure alongside a revised price target of US$50 from US$55, citing business growth excluding MIS as support for what it describes as sustainable double digit top line expansion. Freedom Capital downgraded AtriCure to Hold from Buy and lifted its target to US$57 from US$43, expecting BoX-NoAF POAF data in Q2 2027 to be positive but flagging that earlier supportive data carries caveats, which it thinks reduces the margin for error if results or execution fall short of expectations. Revenue growth assumptions are broadly steady, moving from about 12.33% to about 12.35%, net profit margin expectations remain around 4.55%, future P/E has moved from about 94.5x to about 101.3x, and the discount rate is broadly unchanged, moving from about 7.52% to about 7.55%.

SAFE Fertility Group, or SAFE, has announced its corporate direction under the concept "The Next Chapter of Fertility" on the occasion of celebrating its 20th year. Dr. Wiwat Kwangkananurak, founder and Chief Executive Officer, said the company aims to expand its family care base from 40,000 families to 50,000 families within the next 3-5 years, while driving average revenue growth of 10-15% per year. Key strategies include growth in the Preserve and Prevent markets, as younger generations increasingly turn to egg freezing, sperm freezing, and genetic testing, and expansion of its international patient base, which currently accounts for as much as 50% of all the company's patients, into additional new markets. The concept covers three areas: Prepare, readiness through health and hormone assessments; Preserve, alternative treatment through egg and sperm freezing technology; and Prevent, advance prevention through comprehensive genetic disease screening. The company is also expanding into genetic analysis laboratories under Next Generation Genomic Co., Ltd. Over the longer term of 5-10 years, SAFE aims to propel Thailand to become a Regional Fertility Hub trusted by families across the region.

Analysts at Asia Plus Securities see the return of Middle Eastern tourists as a positive factor for the earnings of private hospital operators in the third quarter of 2026. The number of Middle Eastern tourists in September rose 18.8% year on year, though it fell 43.1% from the previous month on seasonal factors, bringing the third quarter of 2026 up 12.9% year on year and 142.4% from the previous quarter. This reflects travel gradually returning to normal after Middle Eastern patients began recovering from the impact of the Iran war. Although patient numbers at some hospitals have yet to return to last year's levels, most of those coming back are complex and serious cases with high revenue per case and high margins, supporting the prospect that profits will recover faster than revenue. In the third quarter of 2026, tourists from the UAE rose 29.8% and those from Saudi Arabia rose 21%, while Qatar and Oman rose 1% and 4% respectively. BH benefits the most, with Middle Eastern patients accounting for about 23% of its revenue, followed by PR9 and BDMS at about 10% and 4%. Normalised profits for private hospital operators in the third quarter of 2026 are expected to be the strongest of the year, driven by recovering foreign patients, a rise in Thai patients from influenza and COVID-19, and the return of complex cases. The Bangkok floods from 24 to 26 September are expected to have a limited impact.

Dashenlin held an online briefing on its 2026 interim results on September 30, addressing investor questions about negative investing and financing cash flows, convertible bond conversion, and logistics and distribution. The company said the negative investing cash flow mainly stemmed from capital expenditure on new store openings, digitalisation and logistics system construction, as well as consideration paid for pharmacy acquisitions, while the negative financing cash flow was mainly due to continued cash dividends. Operating cash flow remained a net inflow. The 1.405 billion yuan convertible bonds issued by the company will mature on October 21, 2026, and have not yet been converted. The company said its cash reserves are sufficient, and it will assist holders willing to convert, while repaying principal and interest in full and on time to holders who hold to maturity, with controllable redemption risk. On logistics, the company has built a three-tier warehouse network of group warehouses, regional warehouses and district warehouses. As of the end of the reporting period, it had 35 warehouses nationwide, including in Inner Mongolia and Xinjiang, with total warehousing area of 420,000 square metres. Self-operated delivery accounted for more than 85% of total delivery volume, warehouse shipment fulfilment rate reached 99%, and shipment error rate was below 0.008%. The interim report showed revenue of 13.99 billion yuan, up 3.46% year on year; net profit attributable to the parent of 927 million yuan, up 16.10%; non-GAAP net profit attributable to the parent of 931 million yuan, up 18.05%; net operating cash flow of 1.289 billion yuan, down 55.70%; and a proposed cash dividend of 0.41 yuan per share before tax.

Jim Cramer said GRAIL, Inc. could climb much higher after an FDA advisory panel backed its Galleri multi-cancer early detection test, comparing the stock to Moderna when it traded around $120. The panel voted 7-2 with one abstention that Galleri's benefits outweighed its risks, 6-4 on effectiveness and unanimously on safety, though the recommendation is not binding and final approval had not been granted as of October 2, with Reuters reporting a decision is expected in the coming months. GRAIL generated $44.7 million of revenue in the second quarter, up 26% year over year, as Galleri revenue rose 24% to $42.6 million and test volume increased 35% to more than 61,000, while the company posted a $110.2 million net loss and a $90.3 million adjusted EBITDA loss with $861.6 million in cash, cash equivalents and short-term marketable securities at June 30. Moderna, Inc. reported $145 million of revenue in the second quarter against $142 million a year earlier and a $782 million net loss, ending June with $6.9 billion in cash, cash equivalents and investments, and its Phase 3 INTerpath-001 trial of intismeran autogene with Merck's Keytruda met its recurrence-free-survival and distant-metastasis-free-survival endpoints in resected melanoma. Citi analyst Geoff Meacham said on September 30 that Moderna's roughly $80 billion market capitalization was approaching Regeneron's despite materially lower expected revenue and earnings, while GRAIL's bear case rests on adoption and reimbursement, with Galleri costing about $700 out of pocket and generally not covered by Medicare or private insurers.